Study to Assess the Long-term Safety of Dupilumab Administered in Participants ?6 Months to <18 Years of Age With Atopic Dermatitis (AD)

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ?6 Months to <18 Years of Age With Atopic Dermatitis

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: To assess the long-term efficacy of dupilumab in pediatric participants with AD To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab.

Clinical Trial: Study to Assess the Long-term Safety of Dupilumab Administered in Participants ?6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ?6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Recruitment

Summary

Participation Requirements

Description

Tracking Information